Firazyr(icatibant)
Firazyr, Icatibant (icatibant) is a protein pharmaceutical. Icatibant was first approved as Firazyr on 2008-07-11. It is used to treat hereditary angioedemas in the USA. It has been approved in Europe to treat hereditary angioedemas. The pharmaceutical is active against B2 bradykinin receptor. In addition, it is known to target B1 bradykinin receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Firazyr, Icatibant (discontinued: Icatibant)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hereditary angioedemas | EFO_0004131 | D054179 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J1744 | Injection, icatibant, 1 mg |
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hereditary angioedemas | D054179 | EFO_0004131 | — | — | — | 1 | — | 5 | 6 |
| Angioedema | D000799 | EFO_0005532 | T78.3 | — | — | 1 | — | 5 | 6 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Icatibant |
| INN | icatibant |
| Description | ICATIBANT |
| Classification | Protein |
| Drug class | antiasthmatics (bradykinin antagonists) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N=C(N)NCCC[C@H](NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H]1Cc2ccccc2CN1C(=O)[C@H](CO)NC(=O)[C@H](Cc1cccs1)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCNC(=N)N)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 130308-48-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2028850 |
| ChEBI ID | — |
| PubChem CID | 6918173 |
| DrugBank | DB06196 |
| UNII ID | 7PG89G35Q7 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,803 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,580 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use